Eight IPOs joined the public market this past week, joined by ten SPACs. Two companies postponed, both citing market conditions: fitness equipment brand iFIT Health & Fitness (IFIT) and drug developer AEON Biopharma...read more
IsoPlexis, which provides a single-cell proteomics platform for drug development, raised $125 million by offering 8.3 million shares at $15, the midpoint of the $14 to $16 range. At pricing, the company commands a fully diluted market value of $648 million. The...read more
Updated Monday, 10/4. In the first full week of October, seven IPOs are slated to raise $2.0 billion, led by two fitness companies. Fitness chain Life Time Group Holdings (LTH) plans to raise $901 million at a $4.1 billion market...read more
IsoPlexis, which provides a single-cell proteomics platform for drug development, announced terms for its IPO on Friday. The Branford, CT-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of...read more
US IPO Weekly Recap: Healthcare and Canadian crosslistings lead an 8 IPO week
Eight IPOs joined the public market this past week, joined by ten SPACs. Two companies postponed, both citing market conditions: fitness equipment brand iFIT Health & Fitness (IFIT) and drug developer AEON Biopharma...read more
Protein analysis company IsoPlexis prices IPO at $15 midpoint
IsoPlexis, which provides a single-cell proteomics platform for drug development, raised $125 million by offering 8.3 million shares at $15, the midpoint of the $14 to $16 range. At pricing, the company commands a fully diluted market value of $648 million. The...read more
US IPO Week Ahead: New issuers work up a sweat in a fitness-led 7 IPO week
Updated Monday, 10/4. In the first full week of October, seven IPOs are slated to raise $2.0 billion, led by two fitness companies. Fitness chain Life Time Group Holdings (LTH) plans to raise $901 million at a $4.1 billion market...read more
Proteomics platform IsoPlexis sets terms for $125 million IPO
IsoPlexis, which provides a single-cell proteomics platform for drug development, announced terms for its IPO on Friday. The Branford, CT-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of...read more